(2R)-2-amino-1-[4-(hydroxymethyl)piperidin-1-yl]-2-phenylethanone | 313490-57-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-amino-1-[4-(hydroxymethyl)piperidin-1-yl]-2-phenylethanone
• CAS: 313490-57-2
• 化学式: C₁₄H₂₀N₂O₂
• mdl: MFCD13245272
• 分子量: 248.325
• InChiKey: LUFBTBVWMBDXHV-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R)-2-amino-1-[4-(hydroxymethyl)piperidin-1-yl]-2-phenylethanone 、 6-吲哚甲酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以54%的产率得到N-[(1R)-2-[4-(hydroxymethyl)piperidin-1-yl]-2-oxo-1-phenylethyl]-1H-indole-6-carboxamide
  参考文献：
  名称：

  Investigation of the terminal P4 domain in a series of d-phenylglycinamide-based factor Xa inhibitors

  摘要：

  Several P4 domain derivatives of the general D-phenylglycinamide-based scaffold (2) were synthesized and evaluated for their ability to bind to the serine protease factor Xa. Some of the more potent compounds were evaluated for their anticoagulant effects in vitro. A select subset containing various P1 indole constructs was further evaluated for their pharmacokinetic properties after oral administration to rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.105
• 作为产物：
  描述：

  benzyl N-[(1R)-2-[4-(hydroxymethyl)piperidin-1-yl]-2-oxo-1-phenylethyl]carbamate 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 以94%的产率得到(2R)-2-amino-1-[4-(hydroxymethyl)piperidin-1-yl]-2-phenylethanone
  参考文献：
  名称：

  Investigation of the terminal P4 domain in a series of d-phenylglycinamide-based factor Xa inhibitors

  摘要：

  Several P4 domain derivatives of the general D-phenylglycinamide-based scaffold (2) were synthesized and evaluated for their ability to bind to the serine protease factor Xa. Some of the more potent compounds were evaluated for their anticoagulant effects in vitro. A select subset containing various P1 indole constructs was further evaluated for their pharmacokinetic properties after oral administration to rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.105